Literature DB >> 15802873

Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells.

Satoshi Okamoto1, Kiyoshi Ito, Hironobu Sasano, Takuya Moriya, Hitoshi Niikura, Yukihiro Terada, Shinji Sato, Kunihiro Okamura, Nobuo Yaegashi.   

Abstract

The differential diagnosis between reactive mesothelial cells and ovarian carcinoma cells is often difficult in cytologic specimens. Immunocytochemical procedures have been utilized in assisting this differential diagnosis, with limitations. Furthermore, previous studies examined only serous type but not other histological types of ovarian carcinoma cases. Therefore, we evaluated the practical value of various epithelial and mesothelial markers in differential diagnosis of these two types of cells. Various types of ovarian carcinoma (serous, n = 22; mucinous, n = 10; endometrioid, n = 7; clear cell, n = 10) and benign mesothelial tissues (n = 15) were studied by immunohistochemistry. We then studied effective panels of antibodies by immunohistochemistry in 43 cytologic specimens of ascites or peritoneal lavage fluid consisting of 20 reactive mesothelium and 23 adenocarcinomas of the ovary. In the tissue specimens, Ber-EP4, a monoclonal antibody of epithelial antigen, and a polyclonal antibody against calretinin, which is expressed in mesothelium, are used in differentiating reactive mesothelial cells from ovarian carcinoma. In cytologic specimens, the sensitivity and specificity of Ber-EP4 were 100% and 90%, respectively. The sensitivity and specificity of the anti-calretinin antibody were 90% and 91%, respectively. Using multiple regression analysis, the correlation coefficient between epithelial antigen and calretinin reactivity was r = 0.938, with a significance level of p < 0.0001. In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802873     DOI: 10.1620/tjem.206.31

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  Intra-abdominal hyaluronan concentration in peritoneal fluid of horses with sudden signs of severe abdominal pain.

Authors:  James D Lillich; Wendy Ray-Miller; Kristopher S Silver; Elizabeth G Davis; Bruce D Schultz
Journal:  Am J Vet Res       Date:  2011-12       Impact factor: 1.156

2.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

3.  Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.

Authors:  Holly Butler; Omar Saulat; Barbara-Ann Guinn
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

4.  Duodenal and Colonic Metastases of Ovarian Neoplasm.

Authors:  Sandra Barbeiro; Catarina Atalaia Martins; Cláudia Gonçalves
Journal:  GE Port J Gastroenterol       Date:  2015-07-02

5.  Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.

Authors:  Kaire Ojasalu; Corinna Brehm; Kristin Hartung; Maximilian Nischak; Florian Finkernagel; Peter Rexin; Andrea Nist; Evangelos Pavlakis; Thorsten Stiewe; Julia M Jansen; Uwe Wagner; Stefan Gattenlöhner; Andreas Bräuninger; Sabine Müller-Brüsselbach; Silke Reinartz; Rolf Müller
Journal:  Mol Oncol       Date:  2020-06-25       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.